Benefits
Better Bioavailability than Resveratrol
Pterostilbene shows ~80% oral bioavailability in animal (rat) studies vs ~20% for resveratrol — attributed to its dimethylated structure resisting first-pass metabolism (human PK data are limited). Half-life ~7 hours (vs <1 hour for resveratrol). Functionally, pterostilbene may achieve and maintain therapeutic plasma levels more reliably.
Cognitive Function Support
Animal models show pterostilbene improves cognitive performance, particularly age-related cognitive decline. Human cognitive/mood outcome data are not established — the one human RCT (Riche 2014) measured metabolic parameters, not cognition; cognitive evidence remains animal/review-level. Mechanism: SIRT1 activation, anti-inflammatory effects, neurogenesis support.
Cardiovascular Effects
trial showed pterostilbene reduced blood pressure modestly in adults with hyperlipidemia. Note: in the human trial (Riche 2014) pterostilbene alone modestly RAISED LDL cholesterol, so a cholesterol-lowering benefit is not supported. Anti-atherosclerotic mechanisms similar to resveratrol but potentially more bioavailable.
Anti-Inflammatory / Antioxidant
Reduces inflammatory markers, activates Nrf2 antioxidant pathway, modulates NF-κB. Broad anti-inflammatory profile basis for longevity applications.
SIRT1 Activation (Theoretical Longevity)
Like resveratrol, pterostilbene activates SIRT1 — sirtuin pathway involved in longevity. Better bioavailability theoretically translates to more reliable SIRT1 activation. Component of NMN/NR + sirtuin activator longevity stacks.
Mechanism of action
Resveratrol Analog with Better Pharmacokinetics
Dimethylated structure (vs resveratrol's hydroxyl groups) makes pterostilbene more lipophilic — better cell membrane penetration, slower metabolism, longer half-life. Same stilbene core mechanism with improved drug-like properties.
SIRT1 Activation
Activates SIRT1 deacetylase — relevant to longevity, mitochondrial biogenesis, glucose homeostasis. Same mechanism as resveratrol with potentially better bioavailability.
Nrf2 Antioxidant Pathway
Activates Nrf2 transcription factor, upregulating endogenous antioxidant enzymes (SOD, catalase, glutathione synthase). Adaptive antioxidant response.
PPAR-alpha Modulation
Modulates PPAR-alpha — nuclear receptor involved in lipid metabolism. May contribute to cholesterol and triglyceride effects.
Clinical trials
Clinical trial of pterostilbene (125 mg BID) ± grape seed extract vs placebo in 80 adults with hyperlipidemia for 6-8 weeks.
80 hyperlipidemic adults.
Pterostilbene reduced blood pressure modestly; mixed lipid effects (some increase in LDL with pterostilbene alone — concerning); generally well-tolerated. Foundational human trial; results suggest pterostilbene effects are nuanced.
Pharmacokinetic characterization of pterostilbene. The ~80% oral bioavailability figure derives from ANIMAL (rat) PK studies (e.g., Kapetanovic 2011), not a human phase-1 trial — there is no human phase-1 pterostilbene PK trial in the references. Human tolerability up to 250 mg/day comes from the Riche 2014 metabolic/safety RCT.
Healthy adults.
In animal (rat) PK studies, pterostilbene showed ~80% oral bioavailability (vs ~20% for resveratrol). Human data (Riche 2014 RCT) found pterostilbene well-tolerated up to 250 mg/day. No human phase-1 PK trial establishes these bioavailability figures.